Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association最新文献_第7页

Diagnostic Performance of 99mTc-Sestamibi SPECT/CT and 18F-Choline PET/CT in Locating Hyperfunctioning Parathyroid Glands in Patients with Primary Hyperparathyroidism. 99mTc-Sestamibi SPECT/CT和18F-胆碱PET/CT在原发性甲状旁腺功能亢进症患者甲状旁腺定位中的诊断性能

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Pub Date : 2024-04-01 Epub Date: 2024-02-06 DOI: 10.1055/a-2262-9249

Ante Mandic, Ivana Kraljevic, Tanja Skoric Polovina, Karin Zibar Tomsic, Tina Dusek, Annemarie Balasko, Mirsala Solak, Darko Kastelan

{"title":"Diagnostic Performance of 99mTc-Sestamibi SPECT/CT and 18F-Choline PET/CT in Locating Hyperfunctioning Parathyroid Glands in Patients with Primary Hyperparathyroidism.","authors":"Ante Mandic, Ivana Kraljevic, Tanja Skoric Polovina, Karin Zibar Tomsic, Tina Dusek, Annemarie Balasko, Mirsala Solak, Darko Kastelan","doi":"10.1055/a-2262-9249","DOIUrl":"10.1055/a-2262-9249","url":null,"abstract":"Objective: This study aimed to assess the diagnostic performance of 99mTc-sestamibi SPECT/CT and 18F-choline PET/CT in detecting hyperfunctioning parathyroid glands in patients undergoing surgery for primary hyperparathyroidism (PHPT).Methods: A retrospective analysis was conducted on patients who underwent PHPT-related surgery between April 2019 and May 2022. The study focused on patients undergoing either 99mTc-sestamibi SPECT/CT (81 patients) or 18F-choline PET/CT (33 patients) scans before surgery to pinpoint hyperfunctioning parathyroid gland(s). In the majority of patients, 18F-choline PET/CT was performed after negative or inconclusive findings on 99mTc-sestamibi SPECT/CT. Pathohistological reports were utilized as the reference standard for evaluating the accuracy of the imaging findings.Results: The study encompassed 83 patients (70 females, 84.3%) with an average age of 57.2 years (24-80 years). The pathohistological analysis identified a total of 98 glands. In a per-lesion analysis, the detection rate of 99mTc-sestamibi SPECT/CT was 57% (95% CI 45.3-68.1), while the detection rate of 18F-choline PET/CT was 90.3% (95% CI 74.3-98.0).Conclusion: The results of our study showed the significant usefulness of 18F-choline PET/CT in patients with negative or inconclusive results of 99mTc-sestamibi SPECT/CT in accurately locating hyperfunctioning parathyroid glands in PHPT patients.","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"216-220"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139699162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Laparoscopic Adrenal Gland Surgery in Times of COVID - Is a Safety-Interval Before Surgery After COVID-Infection Still Mandatory? COVID 时代的腹腔镜肾上腺手术--COVID 感染后手术前的安全间隔仍是强制性的吗？

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Pub Date : 2024-04-01 Epub Date: 2024-03-08 DOI: 10.1055/a-2269-1594

Lina Lang, Malte Schirren, Ulrich Wirth, Klaus Hofmann-Kiefer, Matthias Kroiss, Jens Werner, Petra Zimmermann

{"title":"Laparoscopic Adrenal Gland Surgery in Times of COVID - Is a Safety-Interval Before Surgery After COVID-Infection Still Mandatory?","authors":"Lina Lang, Malte Schirren, Ulrich Wirth, Klaus Hofmann-Kiefer, Matthias Kroiss, Jens Werner, Petra Zimmermann","doi":"10.1055/a-2269-1594","DOIUrl":"10.1055/a-2269-1594","url":null,"abstract":"Background: Due to a multicenter study early in the coronavirus disease (COVID)-pandemic that revealed an increased risk for postoperative mortality, thromboembolic and pulmonary complications in case of surgery shortly after a COVID infection, current recommendations for planning elective surgeries suggest postponing surgery for at least 7 weeks after COVID infection. However, virus variants have evolved throughout the pandemic, leading to less severe symptoms. Besides, laparoscopic adrenal gland surgery itself is a safe procedure with low morbidity rates. Therefore, this study aimed to compare the perioperative course of patients undergoing laparoscopic adrenalectomy shortly after a COVID-19 infection with those who had not had a recent SARS-CoV-2 infection in 2022.Patients, material, and methods: All patients who underwent laparoscopic adrenalectomy at the Department for General, Visceral and Transplantation Surgery at Ludwig-Maximilian University between January and December 2022 were included.Results: There was no event of thromboembolic or pulmonary complications in the study population. Duration of surgery did not differ between the two groups; neither did the need for postoperative ICU-admittance nor the duration of ICU-stay. Intraoperative FiO2 did not differ, nor did the SpO2 or the number of different catecholamines. There was a slight trend towards higher noradrenaline dosage among patients after COVID-19 infection. Previous COVID infection did not lead to prolonged hospital stays.Conclusion: The results demonstrate that in case of well-standardized surgical procedures, with a limited surgical trauma and the possibility for patients to be mobilized early, surgery shortly after a mild COVID infection seems safe and reasonable.","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"223-226"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140066382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fundamentals of Diabetes Management. 糖尿病管理基础

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Pub Date : 2024-04-01 Epub Date: 2024-02-20 DOI: 10.1055/a-2166-6566

Bernhard Kulzer, Jens Aberle, Thomas Haak, Matthias Kaltheuner, Jens Kröger, Rüdiger Landgraf, Monika Kellerer

引用次数: 0

Dietary Recommendations for Persons with Type 2 Diabetes Mellitus. 2 型糖尿病患者的饮食建议。

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Pub Date : 2024-04-01 Epub Date: 2024-01-29 DOI: 10.1055/a-2166-6772

Thomas Skurk, Anja Bosy-Westphal, Arthur Grünerbel, Stefan Kabisch, Winfried Keuthage, Peter Kronsbein, Karsten Müssig, Helmut Nussbaumer, Andreas F H Pfeiffer, Marie-Christine Simon, Astrid Tombek, Katharina S Weber, Diana Rubin

引用次数: 0

Perioperative Insulin Pump Therapy Decreases Readmission Risk and Improves Outcomes in Patients with Diabetes. 围手术期胰岛素泵疗法可降低糖尿病患者再入院风险并改善疗效。

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Pub Date : 2024-03-01 Epub Date: 2024-02-16 DOI: 10.1055/a-2218-4574

Kun Wang, Fang Bai, Xiaopan Chen, Joshua D Miller, Xue Chen, Chuan Yun, Zhenzhen Sun, Xiaodan Yuan, Qingqing Lou

{"title":"Perioperative Insulin Pump Therapy Decreases Readmission Risk and Improves Outcomes in Patients with Diabetes.","authors":"Kun Wang, Fang Bai, Xiaopan Chen, Joshua D Miller, Xue Chen, Chuan Yun, Zhenzhen Sun, Xiaodan Yuan, Qingqing Lou","doi":"10.1055/a-2218-4574","DOIUrl":"10.1055/a-2218-4574","url":null,"abstract":"Objective: To evaluate the impact of temporary insulin pump use during hospitalization on glycemia, postoperative complications, and cost/utilization in perioperative patients with diabetes.Methods: Patients (n=159) with type 2 diabetes and hospitalized for elective surgery were recruited from three hospitals. Subjects were categorized into the insulin pump group and the multiple daily subcutaneous insulin injection group according to their treatment therapy. Data were collected at admission, discharge, and 3 months post-discharge.Results: Subjects in the CSII group who were still on insulin therapy transitioned from CSII to MDII; however, their daily insulin dosages were lower than those in the MDII group (15.31±10.98 U/d vs. 23.48±17.02 U/d, P=0.015) after discharge. In terms of medical costs, the CSII group had significantly higher hospitalization costs than the MDII group (112.36±103.43 thousand RMB vs. 82.65±77.98 thousand RMB, P=0.043). After 3 months, the CSII group had significantly lower outpatient costs than the MDII group (3.17±0.94 thousand RMB vs. 3.98±1.76 thousand RMB, P ˂ 0.001). In the MDII group, 10 patients reported severe postoperative complications requiring re-hospitalization; there were no similar reports in the CSII group.Conclusion: Temporary use of insulin pump therapy for perioperative patients with diabetes results in a reduction in blood glucose and blood glucose fluctuation during hospitalization, HbA1c, and the risk of postoperative complication and readmission, thus significantly decreasing costs in this complex patient cohort. Further work is needed to better understand indications for utilizing pump therapy based on diabetes phenotype and the complexity of planned surgical intervention.","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"142-151"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139747887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diabetes and Fatty Liver. 糖尿病与脂肪肝

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Pub Date : 2024-03-01 Epub Date: 2024-02-07 DOI: 10.1055/a-2166-6824

Norbert Stefan, Michael Roden

引用次数: 0

FGF19 Promotes the Proliferation and Insulin Secretion from Human Pancreatic β Cells Via the IRS1/GLUT4 Pathway. FGF19通过IRS1/GLUT4途径促进人胰腺β细胞的增殖和胰岛素分泌

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Pub Date : 2024-03-01 Epub Date: 2024-03-21 DOI: 10.1055/a-2250-7830

Ting Zeng, Xi Tang, Xiaosu Bai, Haiyan Xiong

{"title":"FGF19 Promotes the Proliferation and Insulin Secretion from Human Pancreatic β Cells Via the IRS1/GLUT4 Pathway.","authors":"Ting Zeng, Xi Tang, Xiaosu Bai, Haiyan Xiong","doi":"10.1055/a-2250-7830","DOIUrl":"10.1055/a-2250-7830","url":null,"abstract":"Background: Type 2 diabetes mellitus (T2DM) is a commonly observed complication associated with obesity. The effect of fibroblast growth factor 19 (FGF19), a promising therapeutic agent for metabolic disorders, on pancreatic β cells in obesity-associated T2DM remains poorly understood.Methods: Human pancreatic β cells were cultured with high glucose (HG) and palmitic acid (PA), followed by treatment with FGF19. The cell proliferation, apoptosis, and insulin secretion were evaluated by CCK-8, qRT-PCR, ELISA, flow cytometry, and western blotting. The expression of the insulin receptor substrate (IRS)/glucose transporter (GLUT) pathway was evaluated. The interaction between FGF19 and IRS1 was predicted using the STRING database and verified by co-immunoprecipitation and immunofluorescence. The regulatory effects of the IRS1/GLUT4 pathway on human pancreatic β cells were assessed by overexpressing IRS1 and silencing IRS1 and GLUT4.Results: HG+PA treatment reduced the human pancreatic β cell proliferation and insulin secretion and promoted cell apoptosis. However, FGF19 treatment restored these alterations and significantly increased the expressions of IRS1, GLUT1, and GLUT4 in the IRS/GLUT pathway. Furthermore, FGF19 and IRS1 were found to interact. IRS1 overexpression partially promoted the proliferation of pancreatic β cells and insulin secretion through GLUT4. Additionally, the silencing of IRS1 or GLUT4 attenuated the therapeutic effects of FGF19.Conclusion: In conclusion, FGF19 partly promoted the proliferation and insulin secretion of human pancreatic β cells and inhibited apoptosis by upregulating the IRS1/GLUT4 pathway. These findings establish a theoretical framework for the clinical utilization of FGF19 in the treatment of obesity-associated T2DM.","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":"132 3","pages":"152-161"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140186731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapy for Type 1 Diabetes. 治疗 1 型糖尿病。

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Pub Date : 2024-03-01 Epub Date: 2024-02-16 DOI: 10.1055/a-2166-6695

Thomas Haak, Stefan Gölz, Andreas Fritsche, Martin Füchtenbusch, Thorsten Siegmund, Elisabeth Schnellbächer, Harald H Klein, Til Uebel, Diana Droßel

引用次数: 0

Definition, Classification, Diagnosis and Differential Diagnosis of Diabetes Mellitus: Update 2023. 糖尿病的定义、分类、诊断和鉴别诊断：2023 年更新。

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Pub Date : 2024-03-01 Epub Date: 2024-02-20 DOI: 10.1055/a-2166-6643

Stefan Pleus, Andrea Tytko, Rüdiger Landgraf, Lutz Heinemann, Christoph Werner, Dirk Müller-Wieland, Anette-Gabriele Ziegler, Ulrich A Müller, Guido Freckmann, Helmut Kleinwechter, Erwin Schleicher, Matthias Nauck, Astrid Petersmann

引用次数: 0

Correction: Definition, Classification, Diagnosis and Differential Diagnosis of Diabetes Mellitus: Update 2023. 更正：糖尿病的定义、分类、诊断和鉴别诊断：2023 年更新。

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Pub Date : 2024-03-01 Epub Date: 2024-03-14 DOI: 10.1055/a-2277-1648

Stefan Pleus, Andrea Tytko, Rüdiger Landgraf, Lutz Heinemann, Christoph Werner, Dirk Müller-Wieland, Anette-Gabriele Ziegler, Ulrich A Müller, Guido Freckmann, Helmut Kleinwechter, Erwin Schleicher, Matthias Nauck, Astrid Petersmann

引用次数: 0